Breaking Finance News

Merrill Lynch & Co. Inc. announced Bayer (ETR:BAYN), bumping its price target to 105.00EUR earlier today

Having a price of 91.58EUR, Bayer (ETR:BAYN) traded 0.00% even on the day. With the last stock price close up 2.57% relative to the two hundred day moving average, compared to the S&P 500 Index which has decreased -0.01% over the same period. BAYN has registered a 50-day moving average of 0.04EUR and two hundred day average of 0.03EUR. Volume of trade was was down over the average, with 0 shares of BAYN changing hands under the typical 215 shares.

Stating a possible upside of 0.15%, Merrill Lynch & Co. Inc. upped the target price of Bayer (ETR:BAYN) to 105EUR

Previously on Monday August 29 2016, Citigroup Corp. reported on Bayer(ETR:BAYN) raised the target price from 0.00EUR to 120.00EUR. At the time, this suggested an upside of 0.24%.

See Graph Below:

Bayer (ETR:BAYN)

Bayer has a one-year low of 0.03EUR and a one-year high of 0.04EUR. Bayer’s market cap is currently 0.0 EUR.

Brief Synopsis On Bayer (ETR:BAYN)

Bayer AG is a life science company. The Company’s segments are Pharmaceuticals, Consumer Health, Crop Science, Animal Health and Covestro. The Pharmaceuticals segment is engaged in the development of prescription pharmaceuticals; contraceptives, and medical products, such as injection systems and contrast agents for diagnostic procedures. The Consumer Health segment is engaged in the development of over-the-counter medications, dermatology products and nutritional supplements. The Crop Science segment is engaged in the development of product portfolio in the areas of seeds and plant traits, crop protection, home and garden, the green industry and nonagricultural pest control. The Animal Health segment is engaged in the development of veterinary medicines and animal grooming products. Covestro is engaged in the development of raw materials for polyurethanes; polycarbonate resins and sheets; raw materials for coatings, and adhesives and sealants; and selected chemical intermediates.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.